13th Euro Abstracts on a wide range. The increase of the mother's educational level is in signifi cantly positive relationship with the DS person's computing (khi2 = 14,314, p = 0,026), drawing/ writing (khi2 = 21,027, p = 0,002) and reading (khi2 = 22,169, p = 0.001) performance. It has a favourable effect on the development of the basic self-supporting skills (khi2 = 25,571, P < 0.001), and the DS person's social connections. The majority of those lacking friends live with mothers with the lowest qualifi cation (khi2 = 9.799, p = 0.02). The level of happiness was measured on a four-grade scale. Owing to a mental retardation of medium gravity, surveying was carried out in an indirect way, by questioning the parents. The higher parental qualifi cations associated with happier DS people (khi2 = 17,344, p = 0.008). The parents' educational levels are correlated (r = 0.609, P < 0.001). CONCLUSIONS: More qualifi ed parents provide supportive environment rich in stimuli. Higher level of development reduces the DS person's dependence on others, increases their self-estimation, the level of happiness and through this the quality of life improves. It means a smaller burden on the health care system, the society and the family. However the professionals taking part in family support must be reminded that not every family can perform special child educational tasks independently, and they need more intensive family support.
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University of Minnesota, Tucson, AZ, USA; 2 Kantar Health, New York, NY, USA; 3 Kantar Health, Princeton, NJ, USA OBJECTIVES: Existing assessments of the health related quality of life (HRQoL) in patients with multiple sclerosis have focused on persons with the disease. What has not been assessed is the extent to which the presence of multiple sclerosis generates HRQoL defi cits compared to the general population. METHODS: Data are from the internet-based 2008 National Health and Wellness Survey in the UK, France, Spain, Italy and Germany. a total of 53,524 respondents completed the survey form, of whom 308 indicated they had a diagnosis of multiple sclerosis. Respondents completed the SF-12 generic HRQoL instrument. The analysis is based on the summary mental component scores (MCS), physical component scores (PCS) and health state utilities from the SF-6D items derived from the SF-12 instrument. a multivariate analysis (using ordinary least squares) was undertaken with the MCS, PCS and SF-6D utilities as dependent variables. The independent variables included a binary variable for the presence/absence of multiple sclerosis, socio-demographic characteristics, health risk factors (e.g., body mass index), country dummy variables and the Charlson Comorbidity Index (CCI). RESULTS: Persons reporting multiple sclerosis had substantially lower PCS scores (32.19 vs. 48.66; t = 24.60); MCS scores (39.78 vs. 46.53; t = 10.18) and utility scores (0.57 vs. 0.72; t = 23.57). In the multivariate modeling, the defi cit associated with the presence of multiple sclerosis was substantially greater than any other independent variable in the PCS (−12.07; 95% CI: −14.02 to −10.12) and utility models (−0.11; 95% CI: −0.13 to −0.09). The utility decrement in the SF-6D model attributed to multiple sclerosis far outweighed the utility defi cits attributable to the other independent variables. CONCLUSIONS: Compared to the non-multiple sclero-sis population, there are substantial HRQoL defi cits associated with the diagnosis of multiple sclerosis. These defi cits are substantial and far outweigh those attributable to socio-demographic characteristics, health risk factors and the presence of comorbidities. (VNS) . Scope of this work was to estimate hospital costs for neurosurgery and VNS and compare with Regional funding. METHODS: Investigated phases were: Non-Invasive Diagnostics-NID, Invasive-ID, Neurosurgery Intervention-NI or VNS-I, FollowUP-FUP, in 6 referral centres. Average/patient cost was estimated by microcosting; resource consumption by questionnaire; unit costs valued by full hospital costs (staff, operating-room, hospital-stay), outpatient-tariffs (diagnostics), market-prices (drugs, devices) at 2010 values. RESULTS: NID-phase: c5070/adult (c3516-c7356) and c4382/child. Ranges refl ect variability of hospital-stay and staff time; 79% of total cost is due to diagnostics. DI-phase costs c15,900/adult (37%) and c16,261/child (44%). The cost range for adults (c14,098-c17,702) refl ects variability of invasive video-EEG protocols. Regional funding is under-remunerative. Considering individual procedures, video-EEG costs c3,406/adult (cost driver: staff workload); invasive-video-EEG c34,790 (driver: electrodes). For children, video-EEG costs c3,063 and invasive-video-EEG c27,619; lower values are due to higher seizures frequency and shorter duration of recordings. Neurosurgery intervention cost is c16,230/adult and c18,894/child. For adults, variability (c14,730-c18,513) depends on the duration of intervention, number and cost of staffs. Intervention cost is similar in the three Regions and hospital imbalance is the result of under-funding by regional tariffs. VNS insertion cost is c24,543/ adult (c3,518 for the intervention). Under-remuneration by tariffs is confi rmed, even considering regional extra-tariffs for the device. Global treatment path for an adult (NID + intervention + FUP 5°yrs) amounts to c23,571-NI and c33,373-VNSI; for a child c20,066-NI. Regional data: Lombardy, c23,571-NI and c32,244-VNSI, for Lazio c25,571-NI and c34,176-VNSI, for Emilia Romagna c22,886-NI and c34,871-VNSI. CONCLUSIONS: Funding of the management of resistant epilepsies in the target patient appears insuffi cient to cover costs actually incurred by Italian hospitals, irrespective of organization and Regional funding.
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NON-LOCAL PATIENT-LEVEL DATA FOR COST-EFFECTIVENESS ADAPTATION TO THE SWEDISH ENVIRONMENT
Chowdhury CA 1 , Cuche M 2 , Nilsson M 3 , de Bustamante MM 1 , Lukasik KD 1 , Castañeda EC 1 1 Insight Strategy Advisors, New York, NY, USA; 2 Merck Serono S.A., Geneva, Switzerland; 3 Merck AB, Stockholm, Sweden BACKGROUND: Currently, data-access barriers exist throughout key European health-technology assessment countries, including Sweden. Patient registries are of limited use due to frequent lapses in data integrity, completeness and limitations around access to these data. Additionally, data-protection legislation often prohibits the use of existing data from providers and insurance funds. These limitations hinder the development of longitudinal health-technology assessments required to evaluate the cost-effectiveness of new and existing therapeutics. OBJECTIVES: To explore the opportunities and limitations of applying non-local, longitudinal, patient-level treatment and outcomes data to the Swedish environment. METHODS: A large, longitudinal, patient-level treatment and outcomes data set (>55 million US patients from >90 health insurance plans) from the USA was used to create a sample of patients with multiple sclerosis who were undergoing treatment with disease-modifying drugs. Patient outcomes were evaluated with regard to the extent to which patients were adherent to therapy. Based on adherence levels, patient tendency to use incremental health care system resources was assessed. Adaptation to the local Swedish environment was performed by incorporating or acknowledging customary aspects of the Dental and Pharmaceutical Benefi ts Board (Tandvårds-och läkemedelsförmånsverket) cost-benefi t analysis. Costs of outcomes, specifi cally interventions as a result of nonadherence, were based on Swedish cost-estimates from prior independent research. CONCLUSIONS: When performing a cost-effectiveness analysis, incorporation of patient-level data from another country invokes caveats on the results, including differences in access to care, cultural attitudes and social beliefs. However, in the absence of accessible local data, complete and suffi cient data from another country (e.g., the USA) can serve as a surrogate. This may limit the broad acceptance of the study's results; however, it provides quantitatively supported and customized results based upon a robust data set, upon which health care decision-makers can derive resource allocation and prescribing decisions.
